



salvacion

Surveillance and Analysis of COVID-19 in Children Nationwide

CASE BULLETIN #3 SEPT 30, 2021




Data collection is still ongoing. Submit your **CONFIRMED** and **PROBABLE** pediatric COVID-19 patients at salvacion.pidsphil.org



1,811

REPORTED CASES
AS OF SEPT 30, 2021


OUTCOME



AGE AND SEX DISTRIBUTION



DISEASE SEVERITY




COMORBIDITIES

HEMATOLOGIC/ONCOLOGIC DISEASE	7.2%
NEUROLOGIC/DEVELOPMENTAL DISEASE	7.0%
GASTROINTESTINAL DISEASE	5.6%
CARDIAC DISEASE	3.5%
OBESITY	3.3%
KIDNEY DISEASE	3.2%
BRONCHIAL ASTHMA	2.3%
PREMATURITY	2.2%

GENETIC/METABOLIC	1.4%
TUBERCULOSIS	0.9%
ENDOCRINOLOGIC	0.7%
ALLERGIC DISEASE	0.7%
PREGNANCY	0.6%
RHEUMATOLOGIC	0.5%
SMOKING	0.2%
IMMUNODEFICIENCY	0.2%
PSYCHIATRIC	0.1%

CO-INFECTIONS

6.1%	4.6%
SEPSIS	DENGUE FEVER
2.1%	0.9%
HEALTHCARE ASSOCIATED PNEUMONIA	TUBERCULOSIS





salvacion


Surveillance and Analysis of COVID-19 in Children Nationwide

CASE BULLETIN #3 SEPT 30, 2021



Data collection is still ongoing. Submit your **CONFIRMED** and **PROBABLE** pediatric COVID-19 patients at salvacion.pidsphil.org

CLINICAL MANIFESTATIONS



57.2%
FEVER



24.7%
DECREASED APPETITE



14.4%
WATERY STOOLS



5.5%
MUSCLE PAIN



43.3%
COUGH



24.0%
DIFFICULTY BREATHING



13.9%
ABDOMINAL PAIN



4.3%
LOSS OF SMELL



29.4%
COLDS



18.5%
VOMITING



8.7%
SEIZURE



3.3%
LOSS OF TASTE



6.9%
SORE THROAT



2.9%
HEADACHE

2.3%
RASH


COMMON LABORATORY PARAMETERS

(MEDIAN)



	WBC x10 ³ /uL N=1552	NEUTRO- PHILS N=1547	LYMPHO- CYTES N=1546	PLATELETS x10 ³ /uL N=1109	CRP mg/L N=654	ESR mm/hr N=131	PROCAL- CITONIN ng/L N=410	D-DIMER mg/L N=125	FERRITIN ng/L N=188	LDH U/L N=164	IL-6 pg/ml N=69
ASYMPTOMATIC	9.2	0.52	0.37	340	0.6	23	0.11	---	---	---	---
MILD	8.3	0.54	0.36	300	5.0	12.5	0.15	---	---	---	---
MODERATE	9.8	0.56	0.34	296	7.0	27.5	0.30	1.45	175	352	84
SEVERE	10.9	0.61	0.31	249	16.8	36	0.59	2.12	500	471	54
CRITICAL	11.5	0.63	0.28	254	14.4	35.5	3.33	3.32	722	858	149

MANAGEMENT



73.7% NO OXYGEN SUPPORT
26.3% W/ OXYGEN SUPPORT
- NON-INVASIVE 65.1%
- INTUBATED 34.9%



3.1% REMDESIVIR
0.5% OSELTAMIVIR
0.3% LOPINAVIR/RITONAVIR



9.7%
CORTICOSTEROIDS



3.0%
IVIG



0.3%
TOCILIZUMAB



0.3%
CONVALESCENT PLASMA



0.3%
INTERFERON